P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin Lin, Kris C. Wood, Justine C. Rutter et al.|Nature Cancer|2022Cited by 42
Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor modelsMandana T. Manzari, Ashutosh Chilkoti, Grace R. Anderson et al.|Science Advances|2019Cited by 15
Controlling Release Kinetics of an Adjuvant from a Depot Improves the Efficacy of Local Immunotherapy in Metastatic CancerJoshua J. Milligan, Ashutosh Chilkoti, Rohinee Mattikalli et al.|Advanced Science|2025Cited by 6
Abstract LB-274: Overcoming colorectal cancer resistance to death receptor agonists: Design and delivery of treatment combinationsMandana T. Manzari, Ashutosh Chilkoti, Xinghai Li et al.|Cancer Research|2018Cited by 0
Spatiotemporal Control of IL‐12 Delivery Improves Its Efficacy in Treatment of Solid TumorsJonathan C. Su, Ashutosh Chilkoti, Garrett Kelly et al.|Advanced Therapeutics|2025Cited by 0